Santosh, P.
,
Adams, L.
Fiori, F.
Davidović, N.
de Girolamo, G.
Dieleman, G. C.
Franić, T.
Heaney, N.
Lievesley, K.
Madan, J.
Maras, A.
Mastroianni, M.
McNicholas, F.
Paul, M.
Purper-Ouakil, D.
Sagar-Ouriaghli, I.
Schulze, U.
Signorini, G.
Street, C.
Tah, P.
Tremmery, S.
Tuomainen, H.
Verhulst, F. C.
Warwick, J.
Wolke, D.
Singh, J.
Singh, S. P.
Funding for this research was provided by:
FP7 Health (602442)
Article History
Received: 12 November 2019
Accepted: 13 April 2020
First Online: 16 April 2020
Ethics approval and consent to participate
: This study protocol has received a favourable opinion from the NRES Committee London - Camberwell St Giles (reference: 14/LO/1049). All participants gave written informed consent to participate in the study and participants were free to withdraw from the study at any stage.
: Not applicable.
: PS is the co-inventor of the HealthTracker™ and is the Chief Executive Officer and shareholder in HealthTracker™ Ltd. and a contracted Section Editor with BMC Pediatrics. FF is the Chief Technical Officer of HealthTracker™ Ltd.Frank C. Verhulst is a contributing author of the Achenbach System of Empirically Based Assessments (ASEBA), for which he receives remuneration.